KR890700022A - Pharmaceutical Vehicles to Reduce Skin Penetration Flow - Google Patents

Pharmaceutical Vehicles to Reduce Skin Penetration Flow

Info

Publication number
KR890700022A
KR890700022A KR1019880700847A KR880700847A KR890700022A KR 890700022 A KR890700022 A KR 890700022A KR 1019880700847 A KR1019880700847 A KR 1019880700847A KR 880700847 A KR880700847 A KR 880700847A KR 890700022 A KR890700022 A KR 890700022A
Authority
KR
South Korea
Prior art keywords
zinc
active agent
group
glucopyranoside
beta
Prior art date
Application number
KR1019880700847A
Other languages
Korean (ko)
Inventor
엠. 알렌 라리
Original Assignee
원본미기재
케맥스 파마슈우티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 케맥스 파마슈우티칼스 인코포레이티드 filed Critical 원본미기재
Publication of KR890700022A publication Critical patent/KR890700022A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음No content

Description

피부 관통 유동을 감소시키는 약제 비히클Pharmaceutical Vehicles to Reduce Skin Penetration Flow

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 노르디히드로구아이아레트산과 염화아연을 사용한 본 발명의 방법에 의해 성취된 피부 저장효과를 염화아연 없이 같은 화합물을 사용한 것과 비교하여 나타낸 실험 결과표이다.FIG. 1 is a table of experimental results showing the skin storage effect achieved by the method of the present invention using nordihydroguaiaric acid and zinc chloride compared to using the same compound without zinc chloride.

Claims (6)

히드록시, 옥소, 설프히드릴, 아민, 카르복실 및 아연 이온으로 구성되는 그룹으로부터 선택되는 반응성 기를 갖는 약물학적 활성 약제로 되는 피부와 점막의 보유능력을 증진시킨 약제학적 조성물.A pharmaceutical composition for enhancing the retention capacity of skin and mucosa, which is a pharmacologically active agent having a reactive group selected from the group consisting of hydroxy, oxo, sulfhydryl, amine, carboxyl and zinc ions. 제1항에 있어서, 약물학적 활성 약제가 아연의 착화물 또는 킬레이트물인 조성물.The composition of claim 1 wherein the pharmacologically active agent is a complex or chelate of zinc. VP-16(에피포도필로특신 베타-D 에틸리딘 클루코피라노시드-에토포시드); VM-26(에피포도필로특신 베타-D-레닐리딘 글루코피라노시드-데니포시드)：4′-데메틸 에피포도필로톡신 ; 디에틸스틸베스트롤 ; 디트라놀; 시클로포스파미드; 미토마이신; 다우노마이신; 플라티늄 시스-다이만디클로라이드; 아드리아마이신; 및 알로푸리놀; 으로 구성되는 그룹으로부터 선택되는 약물학적 활성 약제의 피부 및 점막 보유를 증진시키는 방법에 있어서, 상술한 약제에 수용성 아연 함유 화합물의 유효량을 첨가하여서 되는 증진방법.VP-16 (Epipodophyllospecial Beta-D Ethylidine Clucopyranoside-Etoposide); VM-26 (Epipodophyllo special beta-D-renilidine glucopyranoside-deniposide): 4'- dimethyl epipodophyllotoxin; Diethyl steel estrol; Ditranol; Cyclophosphamide; Mitomycin; Daunomycin; Platinum cis-dimandichloride; Adriamycin; And allopurinol; A method for enhancing skin and mucous membrane retention of a pharmacologically active agent selected from the group consisting of: an enhancement method by adding an effective amount of a water-soluble zinc-containing compound to the aforementioned agent. 제3항에 있어서, 아연 함유 화합물이 염화아연인 방법.The method of claim 3, wherein the zinc containing compound is zinc chloride. VP-16(에피포도필로특신 배타-D 에틸리덴 글루코피라노시드-에토포시드); VM-26(에피포도필로톡신 베타-D 테닐디딘 글루코피라노시드-테니포시드) ; 4′-에피포도필로톡신 ; 디에틸스틸베스트롤; 디트란을; 시클로포스파미드; 미토마이신; 다우노마이신; 플리티늄 시스-디아민-디클로라이드; 아드리아마이신; 및 알로푸리놀; 으로 구성되는 그룹으로부터 선택되는 약물학적 활성 약제와 유효량의 수용성 아연 함유 화합물로 되는 피부와 점막 보유능력을 증진시킨 약제학적 조성물.VP-16 (Epipodophyllospecific exclusion-D ethylidene glucopyranoside-etoposide); VM-26 (epipodophyllotoxin beta-D tenyldidine glucopyranoside-teniposide); 4′-epipodophyllotoxins; Diethylstilbestrol; Ditran; Cyclophosphamide; Mitomycin; Daunomycin; Plynium cis-diamine-dichloride; Adriamycin; And allopurinol; A pharmaceutical composition for enhancing skin and mucosal retention capacity comprising a pharmaceutically active agent selected from the group consisting of and an effective amount of water-soluble zinc-containing compounds. 제5항에 있어서, 아연 함유 화합물이 염화아연인 조성물.The composition of claim 5 wherein the zinc containing compound is zinc chloride. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019880700847A 1986-11-19 1986-11-19 Pharmaceutical Vehicles to Reduce Skin Penetration Flow KR890700022A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1986/002544 WO1988003799A1 (en) 1986-11-19 1986-11-19 Pharmaceutical vehicles for reducing transdermal flux

Publications (1)

Publication Number Publication Date
KR890700022A true KR890700022A (en) 1989-03-02

Family

ID=22195724

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880700847A KR890700022A (en) 1986-11-19 1986-11-19 Pharmaceutical Vehicles to Reduce Skin Penetration Flow

Country Status (2)

Country Link
KR (1) KR890700022A (en)
WO (1) WO1988003799A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219847A (en) * 1989-06-12 1993-06-15 Shiseido Company, Ltd. Antipruritic composition
ES2062533T3 (en) * 1989-06-12 1994-12-16 Shiseido Co Ltd ANTIPRURITICAL COMPOSITION.
CA2056803A1 (en) * 1990-12-06 1992-06-07 Llyr G. Griffiths Hair treatment composition
CA2184828C (en) * 1994-03-28 2008-08-12 Shanta M. Modak Composition for inactivating irritants in fluids
US7879365B2 (en) 2002-02-07 2011-02-01 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
EP1480517A4 (en) 2002-02-07 2007-08-22 Univ Columbia Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides
US6855341B2 (en) * 2002-11-04 2005-02-15 Jeffrey B. Smith Anti-viral compositions and methods of making and using the anti-viral compositions
EP1651176A4 (en) 2003-07-17 2008-05-07 Univ Columbia Antimicrobial compositons containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660578A (en) * 1957-04-06 1972-05-02 Kyowa Hakko Kogyo Kk Mitomycin c
US4039663A (en) * 1975-03-19 1977-08-02 Societa' Farmaceutici Italia S.P.A. Daunomycins, process for their uses and intermediates
GB1574090A (en) * 1977-07-06 1980-09-03 Drythanol Ltd Dithranol composition for the treatment of psoriasis
US4406881A (en) * 1980-05-20 1983-09-27 Vipont Laboratories Antimicrobial agent
ZA837627B (en) * 1982-10-15 1984-06-27 Procter & Gamble Storage stable topical pharmaceutical composition containing low dielectric solvents
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
EP0111058B1 (en) * 1982-11-26 1987-11-04 Nippon Kayaku Kabushiki Kaisha Process for producing 4'-demethyl-epipodophyllotoxin-beta-d-ethylidene-glucoside and acyl-derivative thereof
US4567253A (en) * 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide

Also Published As

Publication number Publication date
WO1988003799A1 (en) 1988-06-02

Similar Documents

Publication Publication Date Title
CA2316485A1 (en) Sustained-release pharmaceutical composition
TW341514B (en) Aqueous topical pharmaceutical compositions useful for exfoliation and prevention or treatment of acne
CA2328016A1 (en) Formulations for neutralization of chemical and biological toxants
AU3736385A (en) (piperidine-4-yl-amino)-benzimidazoles/imida-20 pyrines
BE901737A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE MYOCARDIAL ISCHEMIA.
KR890700022A (en) Pharmaceutical Vehicles to Reduce Skin Penetration Flow
MD1688F2 (en) Benzothiophene, benzofuran and indolethiazepinons, oxazepinons and diazepinons, pharmaceutical composition, method of inhibiting the leucocytes adherence to the endothelial cells for inflammatory diseases treatment and method of treatment of the mammals affected by the HIV infection
US4136172A (en) Fungicidal composition and method of use
IL42313A (en) Pharmaceutical composition containing glycyrrhetinic acid for the treatment of oesophagitis
KR970706732A (en) ELEUTHEROBLN AND ANALOGS THEREOF < RTI ID = 0.0 >
Tandon et al. Efficacy of combined chelation in lead intoxication
DE59910906D1 (en) SEMI-SOLID AQUEOUS PREPARATIONS FOR ORAL APPLICATION OF TOLTRAZURIL SULPHONE
CA2301889A1 (en) Water-soluble dry compositions
KR950031084A (en) Topical Jinyang Composition
AU689603B2 (en) A pharmaceutical composition for the prevention and/or treatment of viral infections and optionally inflammations as well as a method for the treatment thereof
BR9808722A (en) Pharmaceutical compositions of tizoxanide and nitazoxanide
IL110471A0 (en) Oral water soluble pharmaceutical compositions containing estrone derivative
KR930019808A (en) Detergent composition
DE60012068D1 (en) Continuous aqueous phase composition containing L-2-oxothiazolidine-4-carboxylic acid ".
FR2719771B1 (en) Pharmaceutical compositions containing gemfibrozil.
Giroux et al. Thiol antidote to inorganic mercury toxicity with an uncharacteristic mechanism
GB1434042A (en) Chemical compositions
JPS5788126A (en) Agent for promoting peroral and transvaginal absorption and preparation containing the same
MAEHASHI et al. Arsenic excretion after treatment of arsenic poisoning with DMSA or DMPS in mice
BR9907166A (en) Pharmaceutical composition and process for stabilizing a compound having an optional ester group and an amidine-based group

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application